Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (121-130 of 181) with videos related to

Pageof 19
Sort By:
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Cancer|December 4, 2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationRashmi Kanagal-Shamanna, Preetesh Jain, Keyur P Patel, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Blood|May 24, 2008
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsMohammad Luqman, Sha Klabunde, Karen Lin, et al.
Pageof 19

Showing results (121-130 of 181) with videos related to

Sort By:
Pageof 19
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 StudyJohn C Byrd, Richard R Furman, Steven E Coutre, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
Cancer|December 4, 2018
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationRashmi Kanagal-Shamanna, Preetesh Jain, Keyur P Patel, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
The Lancet. Haematology|December 22, 2015
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 studyCourtney D DiNardo, Naval Daver, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2021
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia ChromosomeKiyomi Morita, Elias Jabbour, Farhad Ravandi, et al.
Blood|May 24, 2008
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cellsMohammad Luqman, Sha Klabunde, Karen Lin, et al.
Pageof 19